Janssen Research & Development, LLC. Advisory Committee Briefing Document. Rivaroxaban for Reducing the Risk of Cardiovascular Events (Cardiovascular Death, Myocardial Infarction and Stroke) After Acute Coronary Syndrome (ACS). Document No.: EDMS-ERI-38428183:2.0 (April 2012)
Available at: